SNY vs. REGN, VRTX, PFE, GSK, BMY, ZTS, ABT, NVS, TAK, and AZN
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Pfizer (PFE), GSK (GSK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Abbott Laboratories (ABT), Novartis (NVS), Takeda Pharmaceutical (TAK), and AstraZeneca (AZN). These companies are all part of the "pharmaceutical preparations" industry.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.
Sanofi has higher revenue and earnings than Regeneron Pharmaceuticals. Sanofi is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Regeneron Pharmaceuticals received 1456 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 66.56% of users gave Regeneron Pharmaceuticals an outperform vote while only 53.23% of users gave Sanofi an outperform vote.
83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Sanofi shares are held by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Regeneron Pharmaceuticals has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Regeneron Pharmaceuticals has a net margin of 29.45% compared to Regeneron Pharmaceuticals' net margin of 10.52%. Regeneron Pharmaceuticals' return on equity of 19.69% beat Sanofi's return on equity.
Regeneron Pharmaceuticals currently has a consensus target price of $981.71, indicating a potential upside of 0.81%. Sanofi has a consensus target price of $55.00, indicating a potential upside of 11.61%. Given Regeneron Pharmaceuticals' higher probable upside, analysts clearly believe Sanofi is more favorable than Regeneron Pharmaceuticals.
In the previous week, Sanofi had 9 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 29 mentions for Sanofi and 20 mentions for Regeneron Pharmaceuticals. Sanofi's average media sentiment score of 1.20 beat Regeneron Pharmaceuticals' score of 0.74 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.
Summary
Regeneron Pharmaceuticals beats Sanofi on 12 of the 18 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
